# Oligodendroglioma anaplásico

> Página oficial: https://raras.org/doenca/oligodendroglioma-anaplasico
> Fonte: Raras.org — Banco de Dados de Doenças Raras em Português (CC BY-NC-SA 4.0)
> Última atualização: 2026-05-07

## Identificadores

- **ORPHA**: 251630 — https://www.orpha.net/en/disease/detail/251630
- **CID-10**: C71.9
- **OMIM**: none — https://omim.org/entry/none

## Descrição clínica

Oligodendroglioma grau III da OMS com características morfológicas malignas focais ou difusas (pleomorfismo nuclear proeminente, mitoses e celularidade aumentada).

## Epidemiologia e herança

- **Prevalência**: <1 / 1 000 000
- **Padrão de herança**: Not applicable

## Genes associados (2)

- **IDH2** — Isocitrate dehydrogenase [NADP], mitochondrial [Biomarker tested in]
  - Função: Plays a role in intermediary metabolism and energy production (PubMed:19228619, PubMed:22416140). It may tightly associate or interact with the pyruvate dehydrogenase complex (PubMed:19228619, PubMed:
- **POT1** — Protection of telomeres protein 1 [Major susceptibility factor in]
  - Função: Component of the telomerase ribonucleoprotein (RNP) complex that is essential for the replication of chromosome termini. Is a component of the double-stranded telomeric DNA-binding TRF1 complex which

## Ensaios clínicos ativos (12)

- **NCT05698524** [RECRUITING]: A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma — https://clinicaltrials.gov/study/NCT05698524
- **NCT04623931** [RECRUITING]: Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas — https://clinicaltrials.gov/study/NCT04623931
- **NCT04541082** [RECRUITING]: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms — https://clinicaltrials.gov/study/NCT04541082
- **NCT04135807** [RECRUITING]: Implantable Microdevice In Primary Brain Tumors — https://clinicaltrials.gov/study/NCT04135807
- **NCT06108206** [RECRUITING]: Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma — https://clinicaltrials.gov/study/NCT06108206
- **NCT00268385** [ACTIVE_NOT_RECRUITING]: Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas — https://clinicaltrials.gov/study/NCT00268385
- **NCT04978727** [ACTIVE_NOT_RECRUITING]: A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma — https://clinicaltrials.gov/study/NCT04978727
- **NCT03975829** [ACTIVE_NOT_RECRUITING]: Pediatric Long-Term Follow-up and Rollover Study — https://clinicaltrials.gov/study/NCT03975829
- **NCT03152318** [ACTIVE_NOT_RECRUITING]: A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 — https://clinicaltrials.gov/study/NCT03152318
- **NCT02192359** [ACTIVE_NOT_RECRUITING]: Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas — https://clinicaltrials.gov/study/NCT02192359

## Importante

O Raras **não diagnostica e não prescreve**. Esta página é educativa e informativa.
Pacientes devem consultar profissionais de saúde qualificados para decisões clínicas.

---

**Citação sugerida**: Raras.org — Oligodendroglioma anaplásico. Disponível em: https://raras.org/doenca/oligodendroglioma-anaplasico
**Formato HTML**: https://raras.org/doenca/oligodendroglioma-anaplasico
**Formato RDF/Turtle**: https://raras.org/api/rdf?orpha=251630